EUVIMEDEUVIMED entdecken
Crossref

Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma

Zhipeng Yang iD, Yanjie Liu, Haoyuan Li, Qisheng Tang, Biao Yang, Zhifeng Shi iD, Ying Mao

Biomacromolecules · 12.02.2024 · 25 (2) · 655-665

DOI: 10.1021/acs.biomac.3c00846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 19.01.2024. Verfasst von Zhipeng Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Engineering and Technology, Academy for Engineering & Technology, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The blood-brain barrier (BBB) and drug resistance present challenges for chemotherapy of glioblastoma (GBM). A microneedle (MN) patch with excellent biocompatibility and biodegradability was designed to bypass the BBB and release temozolomide (TMZ) and PLCG1-siRNA directly into the tumor site for synergistic treatment of GBM. The codelivery of TMZ and PLCG1-siRNA enhanced DNA damage and apoptosis. The potential mechanism behind this enhancement is to knockdown of PLCG1 expression, which positively regulates the expression of signal transducer and activator of transcription 3 genes, thereby preventing DNA repair and enhancing the sensitivity of GBM to TMZ. The MN patch enables long-term sustainable drug release through in situ implantation and increases local drug concentrations in diseased areas, significantly extending mouse survival time compared to other drug treatment groups. MN drug delivery provides a platform for the combination treatment of GBM and other central nervous system diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsAnimalsMiceTemozolomideRNA, Small InterferingDrug Resistance, NeoplasmCombined Modality TherapyCell Line, TumorXenograft Model Antitumor Assays

Substanzen

TemozolomideRNA, Small Interfering

Autor:innen und Institutionen

  • Institute of Biomedical Engineering and Technology, Academy for Engineering & Technology, Fudan University, Shanghai 200433, China.
  • Henan University of Chinese Medicine, Zhengzhou 200433 Henan, China.
  • Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.

ORCID-Profile: Zhipeng Yang, Zhifeng Shi

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Liu, Y., Li, H., Tang, Q., Yang, B., Shi, Z., & Mao, Y. (2024). Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma. Biomacromolecules, 25(2), 655-665. https://doi.org/10.1021/acs.biomac.3c00846

Vancouver

Yang Z, Liu Y, Li H, Tang Q, Yang B, Shi Z, et al. Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma. Biomacromolecules. 2024;25(2):655-665. doi:10.1021/acs.biomac.3c00846

BibTeX
@article{Yang2024,
  author = {Yang, Zhipeng and Liu, Yanjie and Li, Haoyuan and Tang, Qisheng and Yang, Biao and Shi, Zhifeng and Mao, Ying},
  title = {Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma},
  journal = {Biomacromolecules},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {655--665},
  doi = {10.1021/acs.biomac.3c00846}
}
Kostenlos starten →